Levothyroxine Dose Adjustment Guidelines

Introduction to Levothyroxine Therapy

A TSH level greater than 10 mIU/L warrants dose adjustment, regardless of symptoms, as this level of elevation carries approximately a 5% annual risk of progression to overt hypothyroidism and is associated with increased cardiovascular risk 1
The American College of Endocrinology recommends that TSH is the primary marker for monitoring levothyroxine therapy adequacy, and a current TSH of 15 mIU/L clearly indicates undertreatment, even if the FT4 appears within the normal range 1, 2
Persistent TSH elevation greater than 10 mIU/L despite levothyroxine therapy suggests the current dose is insufficient to meet the patient's thyroid hormone requirements, with a strength of evidence level of high 1, 2

The Endocrine Society recommends increasing levothyroxine by 25 mcg daily for patients under 70 years without cardiac disease, with a moderate strength of evidence 1
For patients over 70 years or with cardiac disease, the American Heart Association recommends using smaller 12.5 mcg increments to avoid cardiac complications, with a high strength of evidence 1, 2
The target TSH should be within the reference range of 0.5-4.5 mIU/L, according to the American Thyroid Association, with a high strength of evidence 1, 2

Recheck TSH and free T4 in 6-8 weeks after the dose adjustment to evaluate response, as recommended by the American Association of Clinical Endocrinologists, with a moderate strength of evidence 1, 2
Free T4 helps interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize, with a low strength of evidence 1
Once adequately treated with stable TSH, repeat testing every 6-12 months or if symptoms change, as recommended by the European Thyroid Association, with a moderate strength of evidence 1

Rule out adrenal insufficiency before increasing levothyroxine, particularly if the patient has any history of pituitary disease, autoimmune conditions, or is on immunotherapy, as recommended by the Journal of Clinical Oncology, with a high strength of evidence 3, 1
If central hypothyroidism is suspected, always start corticosteroids several days before thyroid hormone, with a moderate strength of evidence 3
Check morning cortisol and ACTH if there is any suspicion of concurrent adrenal insufficiency, with a low strength of evidence 3

Do not delay treatment waiting for symptoms to develop—TSH greater than 10 mIU/L requires dose adjustment regardless of symptom status, as recommended by the American College of Endocrinology, with a high strength of evidence 1
Avoid excessive dose increases that could lead to iatrogenic hyperthyroidism, which increases risk for atrial fibrillation, osteoporosis, and cardiac complications, with a high strength of evidence 1
Do not adjust doses more frequently than every 6-8 weeks, as levothyroxine requires this time to reach steady state, with a moderate strength of evidence 1